EUCTR2021-003474-31-GR进行中（未招募）1 期
A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are = 2 to < 18 years of age, treatment naive, sitting, and never ambulatory - STEER
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnostic confirmation during screening period of 5q SMA
- •- The patient must be treatment naive (historical or current use) for all SMN-targeting therapies (e.g., risdiplam (Evrysdi) and nusinersen (Spinraza)).
- •- = 2 years and < 18 years of age at screening visit 1
- •- Onset of clinical signs and symptoms at = 6 months of age
- •- Patient must have a complete HFMSE assessment with an available total score, as administered by qualified clinical evaluator during the screening period for trial eligibility
- •- Able to sit independently at screening, but has never had the ability to walk independently.
- •- Estimated life expectancy > 2 years from screening, in the opinion of the Investigator
- •- Meets age-appropriate institutional criteria for use of anesthesia/sedation as assessed by the physician responsible for administering anesthesia/sedation
- •(Full list of inclusion criteria can be found in the clinical protocol Section 5.1)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 125
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Excluding SMA, any medical condition considered clinically significant by the Investigator, including cardiomyopathy, hepatic dysfunction, kidney disorder, endocrine disorder including diabetes
- •mellitus, gastrointestinal disorders, metabolic disorders, untreated B6 deficiency, severe respiratory compromise and significant brain abnormalities at either Screening or Baseline that, in the opinion of the investigator, would interfere with the overall interpretation of safety or efficacy of the study.
- •- Anti-AAV9 antibody titers >1:50 at Screening as determined by ligand binding immunoassay. NOTE: A negative anti-AAV9 antibody titer is defined as =1:50.
- •- Clinically significant abnormalities in test results during screening period and/or during baseline period as determined by the Investigator
- •- Participants will be excluded from the trial for inpatient surgery hospitalization, hospitalization for a pulmonary event, or hospitalization for nutritional support within 2 months prior to Screening and up to Day 1. In addition, patients will not be eligible for the trial if at Screening, inpatient major surgery is planned at any time during the 64-week study. Any other surgeries must not interfere with the ability of the patient to perform the study assessments.
- •- Prior injury (e.g., upper or lower limb fracture) or surgical procedure which impacts the participant's ability to perform any of the outcome measure testing required in the protocol and from which the participant has not fully recovered or achieved a stable baseline upon entry into screening period
- •- Contraindications for lumbar puncture procedure, (including but not limited to cutaneous infection at the treatment site and signs or symptoms of increased intracranial pressure), active administration of any intrathecal therapy, presence of an implanted shunt for the drainage of CSF, presence of an implanted central nervous system (CNS) catheter, or any impediment to CSF access.
- •(Full list of exclusion criteria can be found in the clinical protocol Section
研究者
相似试验
进行中（未招募）
3 期
Randomized, placebo-controlled, double-blind trial of intrathecal (IT) OAV101 administration in patients with later onset Type 2 spinal muscular atrophy (SMA), to evaluate the efficacy and safety.CTRI/2021/11/037956ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Safety and efficacy of Intrathecal OAV101 in Pediatric Patients with Spinal Muscular Atrophy (SMA) (STEER)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2021-003474-31-DKovartis Pharma AG125
已完成
不适用
A double-blind, randomized, sham-controlled study for efficacy and safety of digital therapeutics of the Sleep Index based cognitive Behavioral Therapy for Insomnia : dSIBT-I studyKCT0007823Asan Medical Center50
已完成
不适用
A randomized, double-blind, sham-controlled study of static electric field therapy by high voltage alternating current for active rheumatoid arthritisa randomized, double-blinded, sham-controlled trialJPRN-UMIN000009442Toshikazu Yoshikawa40
已完成
2 期
Very low current brain stimulation (Transcranial Direct Current Stimulation) to improve upper limb and lower limb weakness in stroke patients.CTRI/2017/01/007733Dr Chittaranjan Andrade60